BC Week In Review | May 25, 2018
Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...
BC Extra | May 18, 2018
Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...
BC Week In Review | Dec 1, 2017
Clinical News

Abeona reports top-line Phase I/II data for ABO-102 in mucopolysaccharidosis IIIA

In October, Abeona Therapeutics Inc. (NASDAQ:ABEO) reported top-line data from the first cohort of 3 patients with mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo type A syndrome) in a Phase I/II trial showing that IV ABO-102 (AAV-SGSH)...
BC Week In Review | Oct 20, 2017
Financial News

Abeona raises $92M in follow-on

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) raised $92 million through the sale of 5.8 million shares at $16 in a follow-on underwritten by Jefferies, RBC Capital Markets, Cantor Fitzgerald, FBR Capital Markets, H.C. Wainwright,...
BC Extra | Oct 17, 2017
Financial News

Abeona raises $80M in follow-on

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) raised $80 million through the sale of 5 million shares at $16 in a follow-on underwritten by Jefferies, RBC Capital Markets, Cantor Fitzgerald, FBR Capital Markets, H.C. Wainwright,...
BC Week In Review | Dec 1, 2016
Clinical News

ABO-102: Interim Ph I/II data

Interim data from 3 patients with MPS IIIA in an open-label, U.S. Phase I/II trial showed that a single IV injection of 5x10 12 vg/kg ABO-102 was well tolerated with no treatment-related serious adverse events...
BC Week In Review | Oct 10, 2016
Clinical News

ABO-102: Phase I/II ongoing

A DSMB recommended continuation to the high-dose cohort of an open-label, U.S. Phase I/II trial evaluating single doses of 2 dose levels of IV ABO-102 based on a review of safety data from 3 patients...
BC Week In Review | Aug 22, 2016
Clinical News

ABO-102: Phase I/II ongoing

Abeona enrolled the second patient in an open-label, U.S. Phase I/II trial evaluating single doses of 2 dose levels of IV ABO-102 based on a DSMB review of safety data from the first patient enrolled....
BC Week In Review | May 23, 2016
Clinical News

ABO-102: Phase I/II started

Abeona began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate single doses of 2 dose levels of IV ABO-102 in about 9 patients. Abeona Therapeutics Inc. (NASDAQ:ABEO), Dallas, Texas   Product: ABO-102 (formerly ABX-A...
BC Week In Review | Jun 15, 2015
Company News

Abeona, PlasmaTech Biopharmaceuticals deal

PlasmaTech acquired Abeona for 4 million PlasmaTech shares, or about $31.9 million based on PlasmaTech’s close of $7.98 on May 15, the last trading day before the deal closed. In mid-2015, the company plans to...
Items per page:
1 - 10 of 12